Wegovy’s supply + brewing competition concerns overshadow a decent Q2
04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."
Pages
76
Language
English
Published on
04/08/22
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...